Actinogen Medical Company Description

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases.

The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.

Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Actinogen Medical Limited

Country	Australia
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Steven Gourlay

Contact Details

Address: 109 Pitt Street Sydney, 2000 Australia
Phone	61 2 8964 7401
Website	actinogen.com.au

Stock Details

Ticker Symbol	ACW
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000ACW3
SIC Code	2836

Key Executives

Name	Position
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.	MD, Chief Executive Officer and Director
William Edward Souter BCom, IPAA, LLB (Adel)	Chief Financial Officer
Dr. Dana C. Hilt M.D.	Chief Medical Officer and Member of Depression and Cognition Clinical Advisory Board
Michael Roberts	Head of Investor Relations and Corporate Communications
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.	Head of Clinical Pharmacology and Lead Physician and Depression
Dr. Fujun Li Ph.D.	Head of Manufacturing
Andrew B. Udell B.Sc., M.B.A.	Chief Commercial Officer
Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.	Company Secretary